1 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow UV1 vaccine: new trials by email Literature Review of UV1 vaccine trials Research Report on UV1 vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma UV1 vaccine + leukine, ipilimumab, nivolumab - Cancer, Cancer, Lung | Phase 2 | Active not recruiting | Åslaug Helland | 118 | 2020-05-04 | 2024-02-29 |
| Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma Ipilimumab, UV1 vaccine, GM-CSF - Malignant Melanoma | Phase 1 / Phase 2 | Completed | Ultimovacs ASA | 12 | 2015-02-02 | 2024-12-16 |
Lung Neoplasms (1) · Melanoma (1) · Mesothelioma (1) · Mesothelioma, Malignant (1) · Neoplasms (1)
Ultimovacs ASA (1) · Åslaug Helland (1)
Norway (2) · Australia (1) · Denmark (1) · Spain (1) · Sweden (1)
PMID 34046035, PMID 34059094, PMID 36089578, PMID 39133306, PMID 42322509